New anti-inflammatory drugs! Youshibi cimzia has been approved for a variety of psoriasis in Japan and has been listed in China!

January 30, 2020 / BIOON / -- UCB, a Belgian pharmaceutical giant, recently announced that the Japanese regulatory authority has approved the approval of cimzia (Chinese trade name: shiminjia ®, general name: certolizumab Pegol, peserizumab injection) is used to treat plaque psoriasis, psoriatic arthritis, pustular psoriasis and erythroderma psoriasis With this approval, cimzia has become the first PEGylated anti-tumor necrosis factor - α (TNF - α) drug without Fc domain for the above patients in the Japanese market In adult patients, the approved dose of cimzia is 400mg every two weeks For maintenance dose, consider 200 mg every two weeks or 400 mg every four weeks Cimzia can be administered subcutaneously using a precharge syringe or an autoclicks ® precharge pen Cimzia was launched in Japan in March 2013 for the treatment of rheumatoid arthritis (RA) This product is produced and supplied by youshibi, exclusively distributed and sold by Astaire, and jointly promoted by youshibi Japan and Astaire In Japan, there are about 430000 psoriasis patients For this newly approved psoriasis indication, yoshibi Japan will carry out all promotion activities to expand its dermatology footprint to Japan Cimzia is the only anti TNF - α drug without Fc domain and modified by polyethylene glycol It has a very high affinity for human TNF - α and can selectively neutralize the pathophysiological role of TNF - α Because of its unique molecular structure without Fc domain, cimzia is the only anti-tumor necrosis factor (an-tnf) biological agent that has strong scientific evidence to prove that the drugs will not transfer to the fetus and infant when the women in childbearing age (from pregnancy to late pregnancy and lactation) receive treatment Up to now, cimzia has been approved by many countries and regions in the world for the treatment of a variety of inflammatory diseases, including rheumatoid arthritis, psoriatic arthritis, plaque psoriasis, ankylosing spondylitis, spinal arthritis, Crohn's disease, etc At the end of March 2019, cimzia was approved by the US FDA as a new indication for the treatment of active non radiologic axial spondyloarthroarthritis (NR axspa) in adult patients with inflammatory signs This approval makes cimzia the first drug approved by FDA to treat NR axspa In China, cimzia was approved by the National Drug Administration (nmpa) in July 2019 for the treatment of patients with moderate to severe rheumatoid arthritis (RA) It is particularly worth mentioning that cimzia is the only biological preparation approved in China that can be used for the treatment of rheumatoid arthritis in the whole pregnancy if there is clinical need in the manual In December 2019, cimzia was officially launched in China, which is the first biotherapy approved by the ushibi product portfolio in China, and will also provide an important treatment option for Chinese women who need to manage RA without affecting pregnancy and breastfeeding programs Source: cimzia? (certolizumab PEG) now available for patients in Japan living with multiple psychological diseases